Infection and Drug Resistance,
Journal Year:
2024,
Volume and Issue:
Volume 17, P. 5061 - 5072
Published: Nov. 1, 2024
Using
antimicrobials
wisely
is
crucial
for
effective
treatment
and
reducing
antimicrobial
resistance
(AMR).
As
ocular
infections
can
lead
to
serious
consequences
ophthalmic
surgery
has
a
great
impact
on
patients,
the
application
of
in
ophthalmology
needs
be
managed
standardized
manner.
Small Methods,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 17, 2025
Abstract
Traditional
ophthalmic
formulations
are
characterized
by
low
bioavailability,
short
intraocular
retention
time,
strong
irritation,
and
failure
to
achieve
the
expected
therapeutic
effect
due
special
physiological
structure
of
eye
existence
many
barriers.
Microneedle
drug
delivery
is
a
novel
transdermal
modality.
Responsive
microneedles
defined
as
controllably
releasing
payloads
in
response
stimuli,
including
pH
levels,
temperature,
enzymes,
reactive
oxygen
species
(ROS),
well
external
stimuli
such
magnetic
fields
light.
In
addition
inheriting
advantages
traditional
microneedles,
which
include
enhanced
targeting
permeability,
non‐invasiveness,
painless
application,
integration
with
stimulus‐responsive
materials
enables
responsive
personalized
precision
process,
further
increases
accuracy
efficiency
ocular
treatments,
making
on‐demand
possible.
This
article
systematically
reviews
classification,
mechanisms,
characteristics
provides
detailed
introduction
their
diagnostic
applications
real‐time
monitoring
potential
diseases,
aiming
offer
insights
for
treatment
diseases
future.
Nanomedicine,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 14
Published: Dec. 20, 2024
Leber's
congenital
amaurosis
(LCA)
represents
a
set
of
rare
and
pervasive
hereditary
conditions
the
retina
that
cause
severe
vision
loss
starting
in
early
childhood.
Targeted
treatment
intervention
has
become
possible
thanks
to
recent
advances
understanding
LCA
genetic
basis.
While
viral
vectors
have
shown
efficacy
gene
delivery,
they
present
challenges
related
safety,
low
cargo
capacity,
potential
for
random
genomic
integration.
Non-viral
therapy
is
safer
more
flexible
alternative
treating
underlying
mutation
causing
LCA.
delivery
methods,
such
as
inorganic
nanoparticles,
polymer-based
systems,
lipid-based
bypass
risks
immunogenicity
integration,
potentially
offering
versatile
personalized
patients.
This
review
explores
background
LCA,
emphasizing
mutations
involved,
diverse
non-viral
methods
being
developed.
It
also
highlights
studies
on
animal
models
clinical
trials.
presents
future
perspectives
therapy,
including
integrating
emerging
technologies
like
CRISPR-Cas9,
interdisciplinary
collaborations,
medicine,
ethical
considerations.